Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04962126
Title Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy (FLUORO)
Acronym FLUORO
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Olivia Newton-John Cancer Research Institute
Indications
Therapies
Age Groups: adult | senior
Covered Countries AUS


No variant requirements are available.